Skip to main content

Daniel T. Kajunski

Member

[email protected]

+1.617.348.1715

Share:

Dan is a corporate and securities attorney whose practice spans the full gamut of corporate law. He has advised clients for nearly two decades in public and private equity and debt financings, securities law matters, mergers and acquisitions, and strategic advice on a broad range of other corporate matters. He capably counsels public and private companies with offerings, compliance, and securities questions and leads buyers and sellers throughout the transaction process. Dan represents life sciences companies as well as clients in other technology fields, financial services, and professional services firms.

Dan’s practice focuses primarily on venture finance, securities law and offerings, mergers and acquisitions, and general business and corporate law, primarily for life sciences and technology companies.

VCs, strategic investors, and issuers rely on Dan’s extensive experience in private fund raising, including equity and debt financings. Public companies also turn to him in connection with public and private offerings and their securities law and compliance needs. In addition, both buyers and sellers engage Dan to counsel them in complicated mergers and acquisitions. Dan also regularly advises both private and public companies at various stages of development on general corporate matters.

Prior to joining the firm, Dan served as a law clerk to the justices of the Superior Court of Massachusetts. While in law school, he served as a staff author and comment editor for the Suffolk University Law Review.

Education

  • Suffolk University Law School (JD)
  • Saint Anselm College (BA)

Experience

Offerings for Public Companies

  • Represented Vertex Pharmaceuticals (Nasdaq: VRTX) in over $2.0 billion in equity and debt offerings since 2006
  • Represented ImmunoGen (Nasdaq: IMGN) in approximately $350 million in equity offerings since 2008
  • Represented Amedica (Nasdaq: AMDA) in its IPO
  • Represented the underwriters in the IPO of Calithera Biosciences (Nasdaq: CALA)
  • Represented the underwriters in the IPO of American Depositary Shares of GW Pharmaceuticals (Nasdaq: GWPH) and two additional follow-on offerings

Venture Capital & Strategic Financings

  • Represented a public technology company in the semiconductor and life sciences industry (Nasdaq) in multiple strategic investments
  • Represented a public medical device company (NYSE) in multiple strategic investments
  • Represented Clarus Ventures in its investments in Ophthotech (Nasdaq: OPHT), VBI Vaccines (Nasdaq: VBIV), TyRx Pharma, and Link Medicine
  • Represented a public biotechnology company (Nasdaq) in its strategic equity investment in a private biotechnology company
  • Represented Style Me Pretty in its strategic investment from AOL (NYSE: AOL)
  • Represented Synchroneuron in multiple equity financings
  • Represented TransMolecular in multiple equity and debt financings
  • Represented Ion Torrent Systems in multiple equity financings
  • Represented I-Pulse in multiple equity financings
  • Represented TransForm Pharmaceuticals in multiple equity financings
  • Represented Hemera Biosciences in its Series A financing


Mergers & Acquisitions

  • Represented Brooks Automation (Nasdaq: BRKS) in its purchase of BioStorage Technologies
  • Represented a public biotechnology company (Nasdaq) in its entering into a merger option to acquire a private biotechnology company
  • Represented Clarus Ventures in the reverse merger of VBI Vaccines (Nasdaq: VBIV) with Paulson Capital
  • Represented Orchid BioSciences (Nasdaq: ORCH) in its sale to Laboratory Corporation of America (NYSE: LH)
  • Represented QIAGEN (Nasdaq: QGEN) in its purchase of SA Biosciences
  • Represented TransMolecular in its sale to Morphotek (a subsidiary of Eisai Co. (Tokyo Stock Exchange))
  • Represented Auspice in its sale to the ARRIS Group (Nasdaq: ARRS)
  • Represented EPIX Pharmaceuticals (Nasdaq: EPIX) in its merger with Predix Pharmaceuticals
  • Represented TransForm Pharmaceuticals in its sale to Johnson & Johnson (NYSE: JNJ)
  • Represented FastClick (Nasdaq: FSTC) in its sale to ValueClick (Nasdaq: VCLK)

Viewpoints

Securities & Capital Markets Viewpoints Thumbnail

SEC Expands “Accredited Investor” and “Qualified Institutional Buyer” Definitions

August 31, 2020 | Advisory | By Daniel T. Kajunski, John J. Thomas III

This advisory discusses the SEC's final rule that adopts changes to the definitions of “accredited investor” and “qualified institutional buyer.”
Read more
This advisory discusses the SEC’s approval of an NYSE waiver extension that gives NYSE-listed companies through September 30, 2020 to complete certain capital raising transactions.
Read more
Read about the SEC’s extension of email delivery of certain paper documents, including certain reports by foreign private issuers, as a result of the coronavirus.
Read more
Read about the SEC’s extension of its earlier guidance on manual signatures required under Rule 302(b) of Regulation S-T as a result of the coronavirus.
Read more
For many U.S. public companies, June 30 is the end of the second fiscal quarter, which means it’s time to evaluate their filer status, with any changes taking effect as of the next fiscal year.
Read more
Coronavirus Molecule
On May 14, 2020, the Securities and Exchange Commission (“SEC”) approved changes to the NYSE Listed Company Manual to provide a temporary exception to the shareholder approval rules for certain capital raising transactions as a result of the coronavirus (“COVID-19”) pandemic.
Read more
Read about the SEC’s approved changes affecting shareholder approval rules for certain capital raising transactions.
Read more
Read about the SEC’s FAQs, released on May 4, 2020, providing guidance on the agency’s COVID-19 order giving certain issuers more time to file disclosure reports.
Read more
This advisory reviews the SEC Division of Corporation Finance’s statement of April 23, 2020, including what forms it covers and how filers can submit typed signatures on documents submitted by email.
Read more

Events

Speaker
Feb
11
2015

Public Company Director 101

Corporate Directors Group

Webinar